Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon B Dimmitt

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Annals of the Royal Australasian College of Dental Surgeons|November 4, 2011
General well-being in the new decade--important considerationsSimon B Dimmitt
Archives of Internal Medicine|July 13, 2011
Risk of renal cell carcinoma after hysterectomy: is it all obesity?Simon B Dimmitt
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 23, 2011
Lower drug dose may improve outcomesSimon B Dimmitt
Expert Opinion on Pharmacotherapy|January 26, 2016
Sitagliptin and other 'gliptins'--why prescribe them?Sheila A Doggrell, Simon B Dimmitt
Lancet (London, England)|February 10, 2020
Polypill for prevention of cardiovascular diseasesSimon B Dimmitt, Hans G Stampfer
Expert Opinion on Pharmacotherapy|January 24, 2017
Lipid and other management to improve arterial disease and survival in end stage renal diseaseSimon B Dimmitt, Jennifer H Martin
Journal of the American College of Cardiology|September 7, 2019
Clinically Optimal Versus "Target" Doses in Heart FailureSimon B Dimmitt, Jennifer H Martin
The Medical Journal of Australia|August 24, 2019
Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysisSimon B Dimmitt, Jennifer H Martin
The Medical Journal of Australia|November 4, 2009
Low drug doses may improve outcomes in chronic diseaseSimon B Dimmitt, Hans G Stampfer
Expert Opinion on Drug Safety|April 2, 2014
Gliptins - do they increase cardiovascular risk or benefit?Sheila A Doggrell, Simon B Dimmitt
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Annals of the Royal Australasian College of Dental Surgeons|November 4, 2011
General well-being in the new decade--important considerationsSimon B Dimmitt
Archives of Internal Medicine|July 13, 2011
Risk of renal cell carcinoma after hysterectomy: is it all obesity?Simon B Dimmitt
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 23, 2011
Lower drug dose may improve outcomesSimon B Dimmitt
Expert Opinion on Pharmacotherapy|January 26, 2016
Sitagliptin and other 'gliptins'--why prescribe them?Sheila A Doggrell, Simon B Dimmitt
Lancet (London, England)|February 10, 2020
Polypill for prevention of cardiovascular diseasesSimon B Dimmitt, Hans G Stampfer
Expert Opinion on Pharmacotherapy|January 24, 2017
Lipid and other management to improve arterial disease and survival in end stage renal diseaseSimon B Dimmitt, Jennifer H Martin
Journal of the American College of Cardiology|September 7, 2019
Clinically Optimal Versus "Target" Doses in Heart FailureSimon B Dimmitt, Jennifer H Martin
The Medical Journal of Australia|August 24, 2019
Intensive lipid-lowering therapy in the 12 months after an acute coronary syndrome in Australia: an observational analysisSimon B Dimmitt, Jennifer H Martin
The Medical Journal of Australia|November 4, 2009
Low drug doses may improve outcomes in chronic diseaseSimon B Dimmitt, Hans G Stampfer
Expert Opinion on Drug Safety|April 2, 2014
Gliptins - do they increase cardiovascular risk or benefit?Sheila A Doggrell, Simon B Dimmitt
Pageof 3